Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,160,679
  • Shares Outstanding, K 19,664
  • Annual Sales, $ 251,450 K
  • Annual Income, $ 143,320 K
  • 60-Month Beta 1.40
  • Price/Sales 8.75
  • Price/Cash Flow 11.94
  • Price/Book 2.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.38
  • Number of Estimates 1
  • High Estimate 0.38
  • Low Estimate 0.38
  • Prior Year 2.39
  • Growth Rate Est. (year over year) -84.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
106.11 +3.49%
on 06/11/19
116.88 -6.04%
on 06/19/19
-3.56 (-3.14%)
since 05/24/19
3-Month
106.11 +3.49%
on 06/11/19
130.50 -15.85%
on 04/12/19
-13.31 (-10.81%)
since 03/25/19
52-Week
98.56 +11.42%
on 01/16/19
278.62 -60.58%
on 10/01/18
-82.38 (-42.86%)
since 06/25/18

Most Recent Stories

More News
Ligand Grants Preclinical Candidate Rights to UK-based Firm

Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.

LGND : 109.54 (-0.31%)
NVS : 92.43 (-0.40%)
SAGE : 178.20 (+0.77%)
AMGN : 184.67 (-0.09%)
Ligand Licenses VER250840 to Cumulus Oncology

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840,...

LGND : 109.54 (-0.31%)
AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates

AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.

LGND : 109.54 (-0.31%)
GNMSF : 181.0000 (+0.47%)
AMAG : 8.88 (+3.74%)
FCSC : 1.92 (-2.54%)
Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View

Mallinckrodt (MNK) earnings and sales surpass estimates in the first quarter, which led to an increase in annual guidance.

LGND : 109.54 (-0.31%)
MNK : 8.38 (-0.48%)
RHHBY : 35.2300 (-0.44%)
BMY : 45.84 (+0.35%)
Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss

Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.

MYL : 18.65 (+3.84%)
LGND : 109.54 (-0.31%)
TEVA : 8.81 (+6.79%)
FCSC : 1.92 (-2.54%)
Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin...

LGND : 109.54 (-0.31%)
NOVN : 2.72 (-1.09%)
Watch for Ligand Pharm to Potentially Rebound After Falling 9.18% Yesterday

Ligand Pharm (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $115.25 to a high of $127.29. Yesterday, the shares fell 9.2%, which took the trading range below the 3-day low of $123.14...

LGND : 109.54 (-0.31%)
Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates

Ligand (LGND) delivered earnings and revenue surprises of -95.92% and 13.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

LGND : 109.54 (-0.31%)
Ligand: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Thursday reported first-quarter earnings of $666.3 million.

LGND : 109.54 (-0.31%)
Ligand Reports First Quarter 2019 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2019 and provided an operating forecast and program updates. Ligand...

LGND : 109.54 (-0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade LGND with:

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Key Turning Points

2nd Resistance Point 113.48
1st Resistance Point 111.68
Last Price 109.54
1st Support Level 108.89
2nd Support Level 107.91

See More

52-Week High 278.62
Fibonacci 61.8% 209.84
Fibonacci 50% 188.59
Fibonacci 38.2% 167.34
Last Price 109.54
52-Week Low 98.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar